Stephen Mayo Biography and Net Worth

Director of Allogene Therapeutics

Stephen (Steve) Mayo is the Bren Professor of Biology and Chemistry and Merkin Institute Professor at the California Institute of Technology (Caltech) in Pasadena, California. He served as Vice Provost for Research at Caltech from 2007 to 2010 and Chair of its Division of Biology and Biological Engineering from 2010 to 2020. Dr. Mayo also serves on the Board of Directors of Merck & Co and Sarepta Therapeutics, Inc. He co-founded Molecular Simulations, Inc. (currently Accelrys/Biovia), a computational chemistry company; Xencor, Inc., a publicly traded bio-therapeutics company focused on developing next generation biologics for treating cancer; and Protabit, LLC, a privately held protein engineering company focused on the use of artificial intelligence and machine learning for protein engineering applications. In addition, he serves on the scientific advisory boards of Vida Ventures, Rubryc Therapeutics and Evozyne. Dr. Mayo was elected to the National Academy of Sciences in 2004 for his pioneering contributions in the field of protein design. He served as an elected board member for the American Association for the Advancement of Science from 2010 to 2014 and as a presidential appointee on the National Science Foundation’s National Science Board from 2013 to 2018. Dr. Mayo holds a B.S. in Chemistry from Pennsylvania State University and a Ph.D. in Chemistry from Caltech, and he completed postdoctoral work at both UC Berkeley and Stanford University School of Medicine in chemistry and biochemistry, respectively.

What is Stephen Mayo's net worth?: The estimated net worth of Stephen Mayo is at least $9.53 thousand as of March 5th, 2024. Dr. Mayo owns 6,621 shares of Allogene Therapeutics stock worth more than $9,534 as of December 4th. This net worth approximation does not reflect any other investments that Dr. Mayo may own. Learn More about Stephen Mayo's net worth.
How do I contact Stephen Mayo?: The corporate mailing address for Dr. Mayo and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Stephen Mayo's contact information.
Has Stephen Mayo been buying or selling shares of Allogene Therapeutics?: Stephen Mayo has not been actively trading shares of Allogene Therapeutics over the course of the past ninety days. Most recently, Stephen Mayo sold 10,000 shares of the business's stock in a transaction on Monday, August 7th. The shares were sold at an average price of $4.29, for a transaction totalling $42,900.00. Following the completion of the sale, the director now directly owns 25,328 shares of the company's stock, valued at $108,657.12. Learn More on Stephen Mayo's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 10 times. They sold a total of 169,568 shares worth more than $294,129.46. The most recent insider tranaction occured on October, 21st when CFO Geoffrey M Parker sold 36,744 shares worth more than $46,297.44. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 10/21/2025.

Stephen Mayo Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/7/2023	Sell	10,000	$4.29	$42,900.00	25,328

Stephen Mayo Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.44

$1.41

$1.51

50 Day Range

MA: $1.28

$1.05

$1.52

2 Week Range

Now: $1.44

$0.86

$3.78

Volume

1,536,230 shs

Average Volume

2,359,507 shs

Market Capitalization

$323.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47